PE20210003A1 - Compuestos de purinona y su uso en el tratamiento del cancer - Google Patents
Compuestos de purinona y su uso en el tratamiento del cancerInfo
- Publication number
- PE20210003A1 PE20210003A1 PE2020002005A PE2020002005A PE20210003A1 PE 20210003 A1 PE20210003 A1 PE 20210003A1 PE 2020002005 A PE2020002005 A PE 2020002005A PE 2020002005 A PE2020002005 A PE 2020002005A PE 20210003 A1 PE20210003 A1 PE 20210003A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- purin
- dihydro
- amino
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Measurement Of Radiation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685325P | 2018-06-15 | 2018-06-15 | |
| PCT/EP2019/065686 WO2019238929A1 (en) | 2018-06-15 | 2019-06-14 | Purinone compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210003A1 true PE20210003A1 (es) | 2021-01-05 |
Family
ID=67107385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020002005A PE20210003A1 (es) | 2018-06-15 | 2019-06-14 | Compuestos de purinona y su uso en el tratamiento del cancer |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11884671B2 (enExample) |
| EP (1) | EP3807278B1 (enExample) |
| JP (1) | JP7472044B2 (enExample) |
| KR (1) | KR102793666B1 (enExample) |
| CN (1) | CN112236431B (enExample) |
| AR (1) | AR114971A1 (enExample) |
| AU (1) | AU2019287295B2 (enExample) |
| BR (1) | BR112020025127A2 (enExample) |
| CA (1) | CA3102195A1 (enExample) |
| CL (1) | CL2020003131A1 (enExample) |
| CO (1) | CO2020015758A2 (enExample) |
| CR (1) | CR20200620A (enExample) |
| DO (1) | DOP2020000241A (enExample) |
| EA (1) | EA202190006A1 (enExample) |
| EC (1) | ECSP20080276A (enExample) |
| ES (1) | ES2931448T3 (enExample) |
| IL (1) | IL279370B2 (enExample) |
| JO (1) | JOP20200315B1 (enExample) |
| MA (1) | MA52886A (enExample) |
| MX (1) | MX2020013570A (enExample) |
| NI (1) | NI202000099A (enExample) |
| PE (1) | PE20210003A1 (enExample) |
| PH (1) | PH12020552148A1 (enExample) |
| SG (1) | SG11202012035WA (enExample) |
| TW (1) | TWI820146B (enExample) |
| UA (1) | UA126837C2 (enExample) |
| UY (1) | UY38263A (enExample) |
| WO (1) | WO2019238929A1 (enExample) |
| ZA (1) | ZA202100195B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI899080B (zh) * | 2019-05-27 | 2025-10-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｄｎａ依賴性蛋白激酶抑制劑 |
| CA3159290A1 (en) * | 2019-11-25 | 2021-06-03 | Kevin X Chen | Pyrimidoimidazole compounds used as dna-pk inhibitors |
| EP4086258A4 (en) * | 2019-12-31 | 2023-11-29 | Chengdu Baiyu Pharmaceutical Co., Ltd. | PURINE DERIVATIVE AND ITS MEDICAL USE |
| CN113121573A (zh) * | 2019-12-31 | 2021-07-16 | 成都百裕制药股份有限公司 | 嘌呤衍生物及其在医药上的应用 |
| WO2021136462A1 (zh) * | 2019-12-31 | 2021-07-08 | 成都百裕制药股份有限公司 | 呋喃衍生物及其在医药上的应用 |
| WO2021204111A1 (zh) * | 2020-04-10 | 2021-10-14 | 南京明德新药研发有限公司 | 作为dna-pk抑制剂的氨基嘧啶化合物及其衍生物 |
| AU2021256235B2 (en) * | 2020-04-17 | 2024-05-09 | Kangbaida (Sichuan) Biotechnology Co., Ltd. | Imidazolidinone derivatives and medical use thereof |
| WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
| WO2022017368A1 (zh) * | 2020-07-20 | 2022-01-27 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
| AU2021346954A1 (en) * | 2020-09-24 | 2023-05-25 | Auckland Uniservices Limited | Novel aminopyridines and their use in treating cancer |
| CN114573605A (zh) * | 2020-12-01 | 2022-06-03 | 武汉光谷亚太医药研究院有限公司 | Dna依赖蛋白激酶抑制剂及其应用 |
| TW202241901A (zh) * | 2020-12-21 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘌呤酮衍生物、其製備方法及其在醫藥上的應用 |
| CN114656486B (zh) * | 2020-12-22 | 2023-09-19 | 江苏恒瑞医药股份有限公司 | 嘌呤酮类化合物、其制备方法及其在医药上的应用 |
| CN114656487B (zh) * | 2020-12-22 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 稠合嘧啶类化合物、其制备方法及其在医药上的应用 |
| WO2022135555A1 (zh) * | 2020-12-24 | 2022-06-30 | 江苏恒瑞医药股份有限公司 | 嘌呤酮类化合物、其制备方法及其在医药上的应用 |
| CN116917288B (zh) * | 2021-03-22 | 2026-04-14 | 成都赜灵生物医药科技股份有限公司 | 一种7,9-二氢嘌呤衍生物及其制药用途 |
| WO2023274310A1 (zh) * | 2021-06-29 | 2023-01-05 | 成都百裕制药股份有限公司 | 嘌呤衍生物的晶型及其药物组合物 |
| CN117940437A (zh) * | 2021-09-07 | 2024-04-26 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
| WO2025199376A1 (en) * | 2024-03-22 | 2025-09-25 | Padarn Therapeutics, Inc. | Cdk2 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010002115A (es) * | 2007-08-23 | 2010-06-01 | Aztrazeneca Ab | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos. |
| US8591943B2 (en) * | 2009-04-09 | 2013-11-26 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors |
| SI2493895T1 (sl) | 2009-10-29 | 2017-10-30 | Vectura Limited | Derivati heteroarila, ki vsebujejo N, kot inhibitorji JAK3 kinaze |
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| KR20140022836A (ko) * | 2011-03-11 | 2014-02-25 | 길리아드 칼리스토가 엘엘씨 | 혈액 악성종양에 대한 조합 요법 |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| PE20191474A1 (es) * | 2016-12-20 | 2019-10-16 | Astrazeneca Ab | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer |
-
2019
- 2019-06-06 TW TW108119642A patent/TWI820146B/zh active
- 2019-06-14 IL IL279370A patent/IL279370B2/en unknown
- 2019-06-14 MA MA052886A patent/MA52886A/fr unknown
- 2019-06-14 SG SG11202012035WA patent/SG11202012035WA/en unknown
- 2019-06-14 CR CR20200620A patent/CR20200620A/es unknown
- 2019-06-14 EP EP19734289.2A patent/EP3807278B1/en active Active
- 2019-06-14 UY UY0001038263A patent/UY38263A/es active IP Right Grant
- 2019-06-14 CA CA3102195A patent/CA3102195A1/en active Pending
- 2019-06-14 JP JP2020569143A patent/JP7472044B2/ja active Active
- 2019-06-14 UA UAA202100011A patent/UA126837C2/uk unknown
- 2019-06-14 CN CN201980038412.5A patent/CN112236431B/zh active Active
- 2019-06-14 MX MX2020013570A patent/MX2020013570A/es unknown
- 2019-06-14 PE PE2020002005A patent/PE20210003A1/es unknown
- 2019-06-14 WO PCT/EP2019/065686 patent/WO2019238929A1/en not_active Ceased
- 2019-06-14 BR BR112020025127-5A patent/BR112020025127A2/pt unknown
- 2019-06-14 ES ES19734289T patent/ES2931448T3/es active Active
- 2019-06-14 AR ARP190101659A patent/AR114971A1/es unknown
- 2019-06-14 EA EA202190006A patent/EA202190006A1/ru unknown
- 2019-06-14 US US16/973,862 patent/US11884671B2/en active Active
- 2019-06-14 AU AU2019287295A patent/AU2019287295B2/en active Active
- 2019-06-14 KR KR1020207037917A patent/KR102793666B1/ko active Active
-
2020
- 2020-12-02 CL CL2020003131A patent/CL2020003131A1/es unknown
- 2020-12-07 JO JOJO/P/2020/0315A patent/JOP20200315B1/ar active
- 2020-12-09 DO DO2020000241A patent/DOP2020000241A/es unknown
- 2020-12-10 NI NI202000099A patent/NI202000099A/es unknown
- 2020-12-11 EC ECSENADI202080276A patent/ECSP20080276A/es unknown
- 2020-12-12 PH PH12020552148A patent/PH12020552148A1/en unknown
- 2020-12-15 CO CONC2020/0015758A patent/CO2020015758A2/es unknown
-
2021
- 2021-01-12 ZA ZA2021/00195A patent/ZA202100195B/en unknown
-
2023
- 2023-12-14 US US18/540,129 patent/US20240150355A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221905A1 (es) | Aminas biciclicas como inhibidoras de la cdk2 | |
| CL2022000271A1 (es) | Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina. | |
| DOP2017000015A (es) | Compuestos de heteroarilo y sus usos | |
| CO2022017049A2 (es) | 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer | |
| PE20260440A1 (es) | Compuestos de anillo fusionado | |
| MX2021007833A (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer. | |
| PE20080263A1 (es) | Compuestos de pirrolo-pirimidina y sus usos | |
| CO2017000399A2 (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos | |
| MX2019000451A (es) | Compuesto heterociclico utilizado como inhibidor de fgfr. | |
| MX2022001940A (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2. | |
| MX2023005994A (es) | Composiciones de inhibidores peptidicos del receptor de interleucina-23. | |
| CO2019003974A2 (es) | Compuestos y métodos para la modulación de ido y tdo e indicaciones de estos. | |
| PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
| PE20200335A1 (es) | Compuestos que inhiben la proteina mcl-1 | |
| PE20211868A1 (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cancer | |
| MX2018016419A (es) | Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida. | |
| AR069309A1 (es) | Derivados de imidazo[1,2-a] piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos. | |
| CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| MX2018012609A (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| PE20151982A1 (es) | Derivados de bencimidazolona como inhibidores del bromodominio | |
| PE20181010A1 (es) | Derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarinico 4 (m4) para tratar trastornos neurologicos | |
| EA202190681A1 (ru) | Амиды диметиламиноазетидина в качестве jak ингибиторов | |
| AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
| PE20200932A1 (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 |